Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Nephropathic Cystinosis
2010-018365-34Phase 3
- Sponsor
- Raptor Pharma
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cysteamine in nephropathic cystinosis, sponsored by Raptor Pharma. Primary endpoint: Primary safety endpoints.
02
Drugs
cysteamine
03
Conditions
nephropathic cystinosis
Beyond the preview
Go deeper on 2010-018365-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018365-34.